Loading...
ARGX logo

argenx SENasdaqGS:ARGX 株式レポート

時価総額 US$49.0b
株価
US$782.17
US$990.96
21.1% 割安 内在価値ディスカウント
1Y38.3%
7D0.7%
ポートフォリオ価値
​
表示

argenx SE

NasdaqGS:ARGX 株式レポート

時価総額：US$49.0b

argenx（ARGX）株式概要

商業段階のバイオファーマ企業であるargenx SEは、米国、日本、中国、オランダ、そして国際的に自己免疫疾患治療のための様々な治療法を開発している。 詳細

ARGX ファンダメンタル分析
スノーフレーク・スコア
評価3/6
将来の成長5/6
過去の実績4/6
財務の健全性5/6
配当金0/6

報酬

当社が推定した公正価値より66.8%で取引されている

収益は年間20.5%増加すると予測されています

過去1年間で収益は39.9%増加しました

リスク分析

リスクチェックの結果、ARGX 、リスクは検出されなかった。

ARGX Community Fair Values

Create Narrative

See what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives
Pharmaceuticals & Biotech opportunity
GANX logo
Gain Therapeutics
Fair Value from
US$7.675.4% 割安 内在価値ディスカウント

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.

Read full narrative
Read narrative

argenx SE 競合他社

価格と性能

株価の高値、安値、推移の概要argenx
過去の株価
現在の株価€787.31
52週高値€934.62
52週安値€510.06
ベータ-0.057
1ヶ月の変化2.86%
3ヶ月変化-2.97%
1年変化38.34%
3年間の変化93.51%
5年間の変化201.33%
IPOからの変化3,323.09%

最新ニュース

Recent updates

Seeking Alpha • Dec 17

argenx: TED Phase 3 Failure, Vyvgart Growth, And Why I'm Still A Hold

Summary argenx SE retains a Hold rating due to valuation constraints and pipeline setbacks, despite strong commercial execution with VYVGART. Recent termination of TED and lupus nephritis programs narrows pipeline focus, highlighting management's disciplined capital allocation and early stop rules. VYVGART's label expansion and robust operating leverage drive near-term growth, but blockbuster potential in frontline CIDP remains unproven. ARGX's pipeline remains commercially de-risked, but upside is limited without breakthroughs beyond VYVGART, supporting a cautious stance at the current valuation. Read the full article on Seeking Alpha
Seeking Alpha • Mar 24

Argenx: The Magic May Be Already Priced In

Summary argenx's valuation is stretched: trading at ~90x forward P/E, the upside appears limited. Competitive threats are intensifying with UCB (Rystiggo), J&J (Nipocalimab), and Immunovant (Batoclimab/IMVT-1402). There is a near-term catalyst gap in 2025: Major data readouts (TED, Myositis, Systemic Sclerosis) won’t read out until 2026. I initiate Argenx with a HOLD rating. Read the full article on Seeking Alpha
Seeking Alpha • Feb 27

argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent

Summary argenx reported Q4 earnings today. Vyvgart's strong Q4 2024 performance, driven by the U.S. CIDP launch, positions it for continued growth with upcoming launches and approvals in Europe, Japan, and the U.S. The sales outlook for 2025 looks strong, and I expect Vyvgart to once again exceed Street expectations. The pipeline catalyst calendar is light for 2025, and several far more important readouts of Vyvgart and one of empasiprubart are expected in 2026. Near-term risk comes from Immunovant's batoclimab with data in gMG and CIDP patients that could temporarily impact argenx's share price. ARGX stock's valuation remains on the high side but is supported by strong sales momentum of Vyvgart and the expanding and increasingly productive pipeline. Read the full article on Seeking Alpha
Seeking Alpha • Jan 23

argenx: Lofty Valuation Diminishes Appeal Amid Autoimmune Expansion (Rating Downgrade)

Summary Efgartigimod shows success in myositis trials after prior approvals in gMG/CIDP. Both IV and subcutaneous forms are approved, with Phase 3 myositis trials starting. Q4 2024 revenue beats estimates at $737M, with $2.2B for full year. Company holds strong cash position of $3.4B at year-end. Pipeline includes C2-targeting empasiprubart and multiple preclinical drugs. Vision 2030 aims for 10 indications and 5 Phase 3 candidates. HOLD rating: $40B market cap prices in current potential. High R&D costs and need for clinical wins limit upside despite leadership in FcRn space. Read the full article on Seeking Alpha
Seeking Alpha • Oct 31

Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat

Summary argenx reported strong Q3 results with the sales outperformance being primarily driven by the gMG uptake of Vyvgart. Initial contribution from the CIDP launch also exceeded expectations. The growth outlook for 2025 has further improved after the Q3 results. The pipeline is as busy as ever with an increasing number of registrational trials of Vyvgart and empasiprubart. The valuation is on the high side after the recent and significant share price appreciation, but argenx has the strong and improving growth outlook to back it up. Read the full article on Seeking Alpha
Seeking Alpha • Sep 25

argenx: Myositis Data Could Add Billions In Value

Summary argenx remains a dominant player in the anti-FcRn market, with Vyvgart approved for gMG, CIDP, and ITP in Japan. The ALKIVIA trial aims to expand Vyvgart's use in myositis, a rare autoimmune disease affecting at least 45,000 people in the U.S. Efgartigimod’s FcRn inhibition reduces pathogenic IgG autoantibodies, showing potential across multiple autoimmune diseases. argenx's solid cash reserves and reduced operating loss suggest a strong financial position with a five-year cash runway. ARGX's leadership in the FcRn market supports a bullish outlook, though high expectations make downside risks notable. Read the full article on Seeking Alpha
Seeking Alpha • Jun 28

Argenx: Strong Setup For Outperformance In 2025

Summary Argenx's shares rose after FDA approval of Vyvgart for the treatment of CIDP. The approval expands the addressable market for Vyvgart, and the company will initially target 12,000 patients in the U.S. who are currently not well controlled on other drugs. The filing with the FDA for the prefilled syringe for Vyvgart was completed, and it represents another potential growth driver in 2025 and a key defensive step in the long-term. The current Street revenue consensus for 2025 looks very conservative and the CIDP approval sets the stage for a period of strong commercial outperformance. Read the full article on Seeking Alpha
Seeking Alpha • May 07

argenx: Innovation Over Losses In Autoimmune Arena

Summary argenx stock has decreased by 22% since the last evaluation, reflecting operational challenges and market conditions. The company is facing competition in the clinic, particularly from Immunovant's IMVT-1402 and Johnson & Johnson's nipocalimab. Despite high R&D and SG&A expenses leading to losses, argenx reported substantial revenue growth and maintains a strong cash position. Regulatory progress and potential market expansion for Vyvgart Hytrulo in new therapeutic areas could bolster argenx's market position. Recommend buying argenx shares, noting its potential in the autoimmune sector and a strong balance sheet, suitable for a barbell portfolio. Read the full article on Seeking Alpha
Seeking Alpha • Feb 01

argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion

Summary Vyvgart generated $1.2 billion in net sales in 2023 and is in a good position to continue performing well in 2024 and beyond. Empasiprubart has generated strong results in the first cohort of MMN patients, putting this candidate on investors' radars and offering something other than Vyvgart. Pipeline expansion includes ARGX-213, the next-generation Vyvgart, which could address some of Vyvgart's limitations and extend the patent life of the anti-FcRn franchise. Read the full article on Seeking Alpha
Seeking Alpha • Sep 21

Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod

Argenx (NASDAQ:ARGX) submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of subcutaneous (SC) efgartigimod to treat adult patients with generalized myasthenia gravis (gMG). The Biologics License Application (BLA) was backed by data from a phase 3 trial called ADAPT-SC, which showed noninferiority of SC efgartigimod (1000mg efgartigimod-PH20) compared to intravenously administered Vyvgart (efgartigimod alfa-fcab). SC efgartigimod is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's (NASDAQ:HALO) drug delivery technology ENHANZE, argenx said in a Sept. 21 press release. Argenx noted that ENHANZE helps the subcutaneous injection delivery of biologics which are typically administered via intravenous infusion. Myasthenia gravis is an autoimmune neuromuscular disorder mainly characterized by muscle weakness and muscle fatigue which can make it difficult to chew, swallow, stand and walk, among other things.
Seeking Alpha • Aug 11

Argenx's neuromuscular disorder drug Vyvgart wins approval in EU

The European Commission (EC) approved argenx's (NASDAQ:ARGX) Vyvgart (efgartigimod alfa-fcab) as an add-on to standard therapy to treat adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. The drug is already approved in the U.S. The EC approval follows a positive opinion by a panel of the European Medicines Agency (EMA) in June recommending the approval of the therapy. The Netherlands-based company said it will work with local health authorities to secure market access for Vyvgart across the EU. The EC approval was backed by data from a global phase 3 trial called ADAPT. In April 2022 the company reported data from a phase 3 three-year extension study called ADAPT+. Myasthenia gravis is an autoimmune neuromuscular disorder mainly characterized by muscle weakness and muscle fatigue which can make it difficult to chew, swallow, smile, stand and walk, among other things. ARGX +1.58% to $380.15 premarket Aug. 11
Seeking Alpha • Jul 28

Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M

Argenx SE press release (NASDAQ:ARGX): Q2 GAAP EPS of -$3.81 beats by $0.83. Total operating income of $85.18M (-73.4% Y/Y).
Seeking Alpha • May 25

argenx: A Very Good Start For Vyvgart

argenx beat Q1 2022 revenue estimates thanks to a strong launch of Vyvgart in generalized myasthenia gravis. The early patient numbers look good compared to the launch of Soliris four years ago. The phase 3 results of efgartigimod look somewhat underwhelming on the primary endpoint but mark an important de-risking event. Cash burn will be high this year but should start to decline as Vyvgart sales ramp and the company has a strong balance sheet. The valuation has not come down despite the biotech bear market but ARGX remains well-positioned to deliver shareholder value in the following years.
Seeking Alpha • May 18

argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain

Derivatives markets, used by the market-making community to hedge equity market liquidity trade orders, tell by their component structure and prices the subject stock’s expected coming price range limits. By comparing today’s balance of upside and downside price change prospects with outcome experiences of similar prior forecasts, qualitative comparisons are being made, stock by stock, of investing portfolio candidates. The analysis indicates for each: a) How big a gain; b) How likely to be reached; c) How soon it could happen; d) How much interim loss risk exposure likely. What else is needed? Only Your acceptance of the implication of open-market buyers’ AND sellers’ real-money bets on their judgments of the future, as offered in March.
Seeking Alpha • Mar 07

argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers

Derivatives markets, used by the market-making community to hedge equity market liquidity trade orders, tell by their component structure and prices the subject stock’s expected coming price range limits. By comparing today’s balance of upside and downside price change prospects with outcome experiences of similar prior forecasts, qualitative comparisons are being made, stock by stock, of investing portfolio candidates. The analysis indicates for each: a) How big a gain; b) How likely to be reached; c) How soon it could happen; d) How much interim loss risk exposure exists. What else is needed?  Your acceptance standards of the implication of open-market buyers’ AND sellers’ real-money bets on their judgments of the future, once again.
Seeking Alpha • Dec 22

argenx: Vyvgart's Approval A Key Step For Continued Value Creation

argenx received FDA approval for Vyvgart (efgartigimod) for the treatment of generalized myasthenia gravis. The label looks very favorable, and the only negative is that patients who do not have AChR antibodies are not included. Net price estimate of $225,000 per patient per year looks appropriate and the company is pushing value-based agreements with payers. Vyvgart is well-positioned to become one of the leading treatments for gMG patients. The launch of Vyvgart and multiple late-stage clinical trial readouts are the main value drivers for argenx in the next two years.
Seeking Alpha • Nov 30

argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers

Look for surprise values in underpriced stocks. Not the story issues being ballyhooed by touts and the media – everyone knows them. The hidden values are ones found by experienced professional researchers who know the details of industry group issues and their special strengths. They know when to add them to their institutional employer’s multi-billion-$ portfolio. Like when sudden forced Market-Maker liquidity requires price protection by hedging. The cost and structure of that price-change insurance for the MM, a “trade liquidity requirement” paid by the institutional investor buyer, tells how far the stock’s prices may go. For investor portfolios where wealth-building is a principal objective, this is the place to find near-term capital gain reliability.
Seeking Alpha • Aug 23

argenx: R&D Day Goes Unnoticed

argenx held an R&D day last month and it went largely unnoticed. The company outlined an ambitious 2025 vision for efgartigimod, ARGX-117, and its Immunology Innovation Program. The two new indications for efgartigimod are myositis and bullous pemphigoid. ARGX-117 phase 1 healthy volunteer data look good and supportive of further clinical development in complement-mediated diseases.
Seeking Alpha • Jun 30

argenx: Next Phase Of Growth With Efgartigimod And ARGX-117

One of argenx's main competitors, Immunovant, suffered clinical setbacks this year and these setbacks have further solidified efgartigimod's potential best-in-class position. argenx to become a commercial-stage company by late-2021 with expected efgartigimod approval for generalized myasthenia gravis. Efgartigimod's robust clinical program with five late-stage trials will soon expand with two additional indications. Phase 1 results of ARGX-117 should provide important data in the following weeks. Janssen gave up on cusatuzumab after underwhelming ELEVATE study data and I no longer expect this candidate to create shareholder value.

株主還元

ARGXUS BiotechsUS 市場
7D0.7%1.2%2.1%
1Y38.3%41.9%30.6%

業界別リターン: ARGX過去 1 年間で41.9 % の収益を上げたUS Biotechs業界を下回りました。

リターン対市場: ARGX過去 1 年間で30.6 % の収益を上げたUS市場を上回りました。

価格変動

Is ARGX's price volatile compared to industry and market?
ARGX volatility
ARGX Average Weekly Movement4.3%
Biotechs Industry Average Movement10.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.2%

安定した株価: ARGX 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。

時間の経過による変動: ARGXの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
20081,863Karen Masseyargenx.com

商業段階のバイオファーマ企業であるargenx SEは、米国、日本、中国、オランダ、および国際的に自己免疫疾患治療のための様々な治療法を開発している。同社は、gMGおよび免疫性血小板減少症（ITP）の治療薬としてVYVGARTを、gMGおよび慢性炎症性脱髄性多発神経炎（CIDP）の治療薬としてVYVGART HYTRULOを提供している。また、血清陰性gMG、重症眼筋無力症（MG）、原発性ITP、グレイブ病、筋炎、シェーグレン病、全身性硬化症、AMRの治療薬としてエフガルチギモド、MMN、移植片機能遅延、CIDPの治療薬としてエンパシプラバート、先天性筋無力症候群と脊髄性筋萎縮症の治療薬としてアディマネバートを開発している。さらに、半減期の延長と持続的なIgG減少のために設計された新生児Fc受容体（FcRn）標的抗体ARGX-213、FcRnパイプライン候補のARGX-124を開発中である；炎症治療のためにIL-6を標的とするARGX-109、免疫グロブリンAを標的とするARGX-121、ガレクチン-10に対する抗体を開発するARGX-118、クサツズマブ、ARGX-112、ARGX-114、ARGX-115。また、エフガルチギモドの開発・商業化ではZai Lab社、ヒト疾患の予防・治療薬ENHANZEではHalozyme Therapeutics社、クサツズマブではOncoVerity, Inc.社、ARGX-115ではAbbVie, Inc.社と戦略的パートナーシップおよびライセンス契約を結んでいる。 アルジェンクスSEは2008年に法人化され、オランダのアムステルダムに本社を置いている。

argenx SE 基礎のまとめ

argenx の収益と売上を時価総額と比較するとどうか。
ARGX 基礎統計学
時価総額US$49.00b
収益（TTM）US$1.49b
売上高(TTM)US$4.74b
32.9x
PER（株価収益率
10.3x
P/Sレシオ

ARGX は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
ARGX 損益計算書（TTM）
収益US$4.74b
売上原価US$1.99b
売上総利益US$2.76b
その他の費用US$1.27b
収益US$1.49b

直近の収益報告

Mar 31, 2026

次回決算日

Jul 23, 2026

一株当たり利益（EPS）23.94
グロス・マージン58.11%
純利益率31.40%
有利子負債／自己資本比率0.6%

ARGX の長期的なパフォーマンスは？

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/07 09:10
終値2026/05/07 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

argenx SE 29 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。55

アナリスト機関
null nullBaird
Colleen KusyBaird
Joel BeattyBaird